Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...

HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Novo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

India's drug regulator is increasing checks on weight loss drug sales. This action follows inspections of pharmacies and clinics nationwide...

The diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy stand...

Danish drugmaker Novo Nordisk is set to launch its popular diabetes drug Ozempic in India this month. This move aims to capture a significa...

According to renowned endocrinologist Dr Shashank Joshi, a steep cut in the prices of Wegovy will help improve access and affordability. “B...

Sales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lill...

Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...

Indian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic vers...

India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...

According to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...

The company that reaped nearly 80% of its $16 billion sales from insulin products last year is hopeful for a regulatory approval for its fi...